Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 11, 2016 10:56 AM ET


Company Overview of Reata Pharmaceuticals, Inc.

Company Overview

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases. Its lead product candidates, bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. Bardoxolone methyl is in Phase II clinical development for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial l...

2801 Gateway Drive

Suite 150

Irving, TX 75063

United States

Founded in 2002

60 Employees



Key Executives for Reata Pharmaceuticals, Inc.

Chairman, Chief Executive Officer and President
Age: 61
Founding Scientist and Scientific Advisor
Founding Scientist and Scientific Advisor
Founding Scientist and Scientific Advisor
Founding Scientist and Scientific Advisor
Compensation as of Fiscal Year 2015.

Reata Pharmaceuticals, Inc. Key Developments

Reata Pharmaceuticals Seeks Acquisition

Reata Pharmaceuticals, Inc. is seeking acquisitions. Reata Pharmaceuticals may use a portion of the net proceeds to acquire complementary businesses, products, or technologies, although we have no present commitments or agreements for any specific acquisitions.

Reata Pharmaceuticals, Inc Receives FDA Clearance for its RTA 744 to Begin Clinical Development

Reata Pharmaceuticals announced that its lead development candidate, RTA 744, has received FDA clearance to begin clinical testing in patients with advanced brain cancers.

Reata Enrolls First Patient in the MOXIe Study

Reata announced enrollment of the first patient in a Phase 2 dose-ranging study examining the safety, tolerability, and efficacy of RTA 408 Oral Capsules versus placebo for the treatment of patients with Friedreich's ataxia. MOXIe (A two-part, randomized, placebo-controlled Phase 2/3 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia) is a multi-center study in approximately 52 patients and is designed to support a potential NDA submission. Part 1 of the study is a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of RTA 408 at 2.5 mg, 5 mg, and 10 mg in patients with Friedreich's ataxia. Part 2 of the study is a randomized, placebo-controlled, double-blind, parallel-group study to evaluate the safety, efficacy, and pharmacodynamics of up to 2 dose levels of RTA 408. The study is designed to evaluate a variety of clinical, and biochemical endpoints, including exercise capacity and quality of life measures.

Similar Private Companies By Industry

Company Name Region
Callida Genomics, Inc. United States
Preventive Medical Technologies United States
Alidex, Inc. United States
SpeciGen Corp. United States
Progenesis Technologies, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Reata Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at